The pharmacogenomics market is projected to reach US$ 14,107.80 million by 2028 from US$ 7,087.81 million in 2021; it is expected to grow at a CAGR of 10.3% from 2021 to 2028.
The increasing prevalence of chronic diseases is one of the most critical factors driving the growth of the market. Many older adults (>60%) suffer from two or more chronic conditions. Twin studies stated that genes can cause chronic conditions, such as cardiovascular disease (CVDs), diabetes, obesity, RA, Alzheimer's disease (AD), and depression. Using molecular genetic data from genome-wide association studies (GWAS), it is now possible to measure individual-level risks for these chronic diseases. According to the Centers for Disease Control and Prevention (CDC), in 2020, nearly 6 in 10 people in the US suffered from at least one chronic disease, and 4 in 10 people had two or more chronic conditions. The increasing incidence of chronic diseases is triggering the demand of pharmacogenomic technologies for developing novel therapies.
Customize This Report To Suit Your Requirement
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities
Pharmacogenomics Market: Strategic Insights

- Get Top Key Market Trends of this report.This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Customize This Report To Suit Your Requirement
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities
Pharmacogenomics Market: Strategic Insights

- Get Top Key Market Trends of this report.This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
North America is likely to dominate the pharmacogenomics market during 2021–2028. The US holds the largest share of the market in North America and is expected to continue this trend during the forecast period. The pharmacogenomics market in the US is expected to grow in the coming years due to rising research activities for developing precision medicine to treat cancer, increasing presence of leading biopharmaceutical and pharmaceutical companies, and growing pharmacogenomic research in the country. The adoption rate of pharmacogenomics-based cancer treatment is rising continuously, and the leading market players are introducing several novel products associated with this approach. Also, the support of the regulatory agencies is expected to drive the market in the US during the forecast period. Currently, several clinical trials are investigating pharmacogenomics technology for developing precise medications and improving the overall response rate of the treatment. In May 2021, US Food and Drug Administration (FDA) approved Lumakras (Sotorasib) for a targeted therapy for non-small cell lung cancer patients with tumors that express the G12C mutation in the KRAS gene.
Market Insights
Growing Funding for Pharmacogenomic Research Drives Market Growth
Genomic sequencing is increasingly used in clinical practice, and over the next five years, genomic data from over 60 million patients are expected to be generated within the healthcare system. Pharmacogenomics is rapidly transitioning into clinical practice, and implementation into healthcare systems supported by government investment is totaling over US$ 4 billion in at least 14 countries.
The UK has announced the world’s largest genome project as a part of EURO200 million public–private collaboration between charities and pharma. The country has already developed the largest genome database in the world through the 100,000 genome projects led by Innovate UK as a part of the UK Research and Innovation. The project will fund researchers and industries to combine data and real-world evidence from the UK healthcare services and create new products and services that can diagnose diseases efficiently.
Moreover, in August 2018, Boston Scientific Corporation, a Massachusetts-based company, announced it landed US$ 4.3 million in seed funding and partnered with Veritas Genetics. The funds will support the company’s mission to enter the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data.
Technology-Based Insights
Based on technology, the pharmacogenomics market is segmented into PCR, sequencing, microarray, gel electrophoresis, mass spectrometry, and others. The market for the PCR segment is further segmented into standard PCR, real time PCR, and digital PCR. The PCR segment is expected to account for the largest share of the pharmacogenomics market during 2021–2028. Polymerase chain reaction (PCR) is a commonly used technology to rapidly produce millions to billions of copies of a specific DNA sample, allowing scientists to take a small sample of DNA and amplify it to a significant enough amount to investigate in detail. The PCR technologies plays a key role in gene cloning and manipulation, DNA cloning, gene mutagenesis, functional analysis of gene, detection of pathogens, and drug resistence assay. Various pharmaceutical and biopharmaceutical companies offer PCR solutions for pharmacogenomic and drug development applications. For instance, Thermo Fisher Scientific, Inc offers real time PCR solutions for the pharmacogenomic application.
Application – Based Insights
Based on application, the pharmacogenomics market is segmented into drug discovery, oncology, neurology and psychiatry, pain management, cardiovascular diseases, and others. The oncology segment holds a considerable market share and is projected to continue its dominance during the forecast period. Cancer pharmacogenomics has contributed several essential discoveries to current cancer treatment, changing the paradigm of treatment decisions. World Health Organization (WHO) stated that cancer reckoned for roughly 10 million demises in 2020. Furthermore, as per the data of American Cancer Society, the global burden of carcinoma is anticipated to rise to 27.5 million fresh cases and 16.3 million cancer deaths by year 2040. Such high figures denote that the rising incidence of cancer is creating a requirement for primitive diagnosis and preventive cure. There are numerous methods, such as PCR, INAAT, and NGS, to diagnose carcinoma comprehending. The conception of PCR (polymerase chain reaction) led to an enormous advancement in clinical DNA testing. PCR-based methodologies demand straightforward instrumentation and infrastructure, exploit only minute quantities of biological material, and are extensively harmonious with clinical routine. The application of pharmacogenomics in oncology is significant because of the tapered therapeutic index of chemotherapeutic drugs and the risk for life-threatening adverse effects.
End User – Based Insights
Based on end user, the pharmacogenomics market is segmented into hospitals and clinics, biopharmaceutical companies, CROs and CDMOs, and others. The CROs and CDMOs segment holds a considerable market share and is projected to continue its dominance during the forecast period. The contract research organization (CRO) helps various companies and organization by conducting the clinical trial of their developed products and technologies, whereas the contract development and manufacturing organizations (CDMO) assist the companies in development and manufacturing of the products. The CROs offer services, such as project management, database design and build, data entry and validation, clinical trial data management, medicine and disease coding, quality and metric reporting, statistical analysis plans and reports, validation programming, and safety and efficacy summaries and final study reports. CROs also provides some other services such as gene services, cloning services, and expression.
Companies operating in the pharmacogenomics market adopt the inorganic growth strategy to meet the evolving customer demands across the world, which involves acquisitions, mergers, and collaborations with local and international players in the global market.
Pharmacogenomics Market Regional Insights
The regional trends and factors influencing the Pharmacogenomics Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Pharmacogenomics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

- Get the Regional Specific Data for Pharmacogenomics Market
Pharmacogenomics Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 7.09 Billion |
Market Size by 2028 | US$ 14.11 Billion |
Global CAGR (2021 - 2028) | 10.3% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By Technology
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
Pharmacogenomics Market Players Density: Understanding Its Impact on Business Dynamics
The Pharmacogenomics Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Pharmacogenomics Market are:
- F. Hoffmann-la Roche Ltd
- Abbott
- Oxford Nanopore Technologies
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
Disclaimer: The companies listed above are not ranked in any particular order.

- Get the Pharmacogenomics Market top key players overview
Pharmacogenomics Market – Segmentation
- Based on technology, the pharmacogenomics market is segmented into PCR, sequencing, microarray, gel electrophoresis, mass spectrometry, and others. The market for the PCR segment is further segmented into standard PCR, real time PCR, and digital PCR.
- By application, the pharmacogenomics market is segmented into drug discovery, oncology, neurology and psychiatry, pain management, cardiovascular diseases, and others.
- Based on end User, the pharmacogenomics market is segmented into hospitals and clinics, biopharmaceutical companies, CROs and CDMOs, and others.
- By Geography, the intradermal injection market is segmented in North America (the US, Canada, and Mexico), Europe (France, Germany, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (Australia, China, India, Japan, South Korea, and the Rest of APAC), Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of MEA), and South and Central America (Brazil, Argentina, and the Rest of SCAM).
F. Hoffmann-la Roche Ltd; Abbott; Oxford Nanopore Technologies; Thermo Fisher Scientific Inc; Illumina, Inc; QIAGEN; Agilent Technologies, Inc; Myriad Genetics, Inc; Admera Health; and Dynamic DNA Laboratories are a few companies operating in the pharmacogenomic market.
Frequently Asked Questions
Which is the most influencing segment growing in the pharmacogenomics market report?
The global pharmacogenomics market based on technology is segmented into sequencing, PCR, gel electrophoresis, mass spectrometry, microarray, and others. In 2021, the PCR segment held the largest share of the market by technology and it is expected to witness fastest CAGR during 2021 to 2028, due to increasing utilization of this technology at global level.
What is the market value of pharmacogenomics market based on region?
The global pharmacogenomics market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The North American area holds the largest market for pharmacogenomics. The United States held the most significant pharmacogenomics market and is expected to grow due to factors such as the increasing prevalence of chronic diseases and growing investments while the technological advancements by key players in pharmacogenomics is also boosting the growth rate in US.
The Asia Pacific region is expected to account for the fastest growth in the pharmacogenomics market. In Japan, India and South Korea, the market is expected to grow owing to the rapid development of research organizations and biopharmaceutical companies.
What are the factors impacting for the Pharmacogenomics market?
Several factors are believed to affect pharmacogenomics market in the coming years. Factors such as growing adoption of personalized therapies, increasing prevalence of chronic diseases, and growing funding in this sector are driving the market growth. However, lack of skilled professionals is likely to hamper the growth of the market.
Who are the major players in the pharmacogenomics market?
The pharmacogenomics market majorly consists of the players such as F. Hoffmann-la Roche Ltd; Abbott; Oxford Nanopore Technologies; Thermo Fisher Scientific Inc.; Illumina, Inc.; QIAGEN; Agilent Technologies, Inc.; Myriad Genetics, Inc.; Admera Health; Dynamic DNA Laboratories among others..
What is Pharmacogenomics?
Pharmacogenomics is a branch of science, which studies the role of gene over the activity of a drugs and hence helps the refreshers in predicting the response of novel as well as previously available therapies. Pharmacogenomics has direct application in the development of personalized medicine by testing single or multiple genes that are related to the disease. The main aim of this technology is to reduce the occurrence of treatment related adverse events and reduction in overall cost of treatment. The growing cases of ADRs and increasing demand of personalized therapies are expected to trigger the growth rate of this segment.
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials
Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Identifying Emerging Markets
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Boosting Operational Efficiency
- Strategic Planning
- Investment Justification
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.















The List of Companies - Pharmacogenomics Market
- F. Hoffmann-la Roche Ltd
- Abbott
- Oxford Nanopore Technologies
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- QIAGEN
- Agilent Technologies, Inc.
- Myriad Genetics, Inc.
- Admera Health
- Dynamic DNA Laboratories


